SME
IPO ·
NSE SME
Bio Medica Laboratories Ltd
Listed
Incorporated in August 2015, Bio Medica Laboratories specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the-counter (OTC) medications in liquid and
Issue details
Price band
₹132 – ₹139
Face value
₹10
Lot size
1,000 shares
Minimum investment
₹2,78,000
Issue size
₹52.43 Cr
Fresh issue
₹44.56 Cr
Offer for sale
₹5.24 Cr
Issue type
Book Built
Exchange
NSE SME
Key dates
Opens
21 May 2026
Closes
25 May 2026
UPI mandate cut-off
5:00 PM on 25 May 2026
Allotment
26 May 2026
Refunds
27 May 2026
Shares in demat
27 May 2026
Listing
29 May 2026
Subscription and listing
Subscription
2.23x
Listing price
₹111.20
Registrar
Skyline Financial Services Pvt Ltd
Lead manager
Narnolia Financial Services
Subscription by category
Total
2.23x
Total applications
3,036
Listing day
Issue price
₹139
Open
₹111.20
High
₹116.75
Low
₹105.65
Day close
₹115.80
Listing gain at open
-20.00%
Issue structure
Shares reserved per category and share of the total issue
QIB Shares Offered
36,000
0.95%
NII Shares Offered
17,55,000
46.53%
bNII > ₹10L
11,70,000
31.02%
sNII < ₹10L
5,85,000
15.51%
Retail Shares Offered
17,92,000
47.51%
Market Maker Shares Offered
1,89,000
5.01%
Total Shares Offered
37,72,000
100.00%
Finaccle’s quick read
Neutral
FY25 income up 150%, PAT up 292%, ROE 54.41%, D/E 2.23, post-issue P/E 13.45x.
A rules-based screen of growth, margins, debt and valuation, built from the offer document and data on Chittorgarh.com. It is for information only and is not investment advice or a recommendation to buy or sell. Read the RHP and speak to a SEBI-registered adviser before you apply.
About the company
Incorporated in August 2015, Bio Medica Laboratories specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the-counter (OTC) medications in liquid and dry-powder injectable forms.der injectables. These injectables are available in both single-dose and multi-dose formats, serving the needs of both human and veterinary healthcare.
Founded
Promoters
Promoter holding
Financial performance
Period
PAT
ROE
54.41%
ROCE
23.22%
Debt / equity
2.23
PAT margin
30.35%
P/E post issue
13.45
Market cap
₹174.79 Cr
Use of IPO money
Repayment of loan
₹6.50 Cr
Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises
₹28.50 Cr
General Corporate Purposes
₹7.05 Cr
Issue Expense
₹5.14 Cr
Strengths
✓
Multi-product capability and diversified product portfolio Experienced promoters, management and employees
✓
Quality assurance Established client relationship
✓
Revenue up 150% in FY25 to ₹38.33 Cr
✓
PAT up 292% in FY25 to ₹9.79 Cr
✓
PAT margin of 30.35%
Risks to watch
!
High leverage: debt to equity 2.23
!
SME platform: large lot size and thinner trading liquidity
Planning to take your own company public?
Every listing on this page started with a growing business that got its numbers, governance and paperwork ready for investors. If you are a promoter weighing an SME or main board IPO, we can tell you where you stand and what it will take.
Talk to our IPO Advisory team for readiness planning, or our IPO Consultancy team to run the listing end to end.
Last updated:
Information is compiled from exchange notices and the company’s offer document. It is for general information only and is not investment advice or a recommendation to apply. Read the prospectus before investing.